Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.53 |
| ▸ | CTSS | P25774 | 3/20 | 0.53 |
| ▸ | CTSK | P43235 | 3/20 | 0.53 |
| ▸ | CTSB | P07858 | 2/20 | 0.53 |
| ▸ | CTSC | P53634 | 2/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 16/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3813965 | 0.86 | CTSL (0.54) | CTSLCTSSCTSKCTSBCTSC | |
| SCHEMBL3810406 | 0.86 | CTSL (0.54) | CTSLCTSSCTSKCTSBCTSC | |
| SCHEMBL3806244 | 0.84 | CTSL (0.54) | CTSLCTSSCTSKCTSBCTSC | |
| SCHEMBL3811249 | 0.84 | CTSL (0.58) | CTSLCTSSCTSKCTSBCTSC | |
| SCHEMBL3810789 | 0.83 | CTSL (0.53) | CTSLCTSSCTSKCTSBCTSC | |
| SCHEMBL3806375 | 0.83 | CTSL (0.51) | CTSLCTSSCTSKCTSBCTSC | |
| SCHEMBL3815837 | 0.83 | CTSL (0.51) | CTSLCTSSCTSKCTSBCTSC | |
| SCHEMBL3811443 | 0.82 | CTSL (0.53) | CTSLCTSSCTSKCTSBCTSC | |
| SCHEMBL3810695 | 0.82 | CTSL (0.53) | CTSLCTSSCTSKCTSBCTSC | |
| SCHEMBL3810252 | 0.82 | CTSL (0.43) | CTSLCTSSCTSKCTSBCTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264498-A1 | Cathepsin C Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | claimed |
| WO-2009129365-A1 | CATHEPSIN C INHIBITORS | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | WO | disclosed |
| US-20090264498-A1 | Cathepsin C Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
| US-20090264498-A1 | Cathepsin C Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
| US-20090264498-A1 | Cathepsin C Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264498-A1 | Cathepsin C Inhibitors | CTSF, CTSZ, CTSG | CTSL 9/4885CTSS 5/4885CTSK 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.